12-17-21 Monoclonal Shortage Plan

Growing every day to care for you

LMH Health is investing in new patient-centered programs, technologies and facilities that will make a real difference in access, convenience and expanded clinical services.

2023 LMH Health Annual Report

2023 LMH Health Foundation Annual Report

Friday, December 17, 2021

Monoclonal Shortage Plan

Download Plan (pdf)

Due to the rapidly changing nature of monoclonal allocations within the pandemic, we must prepare for shortages to optimize access for our highest risk patients. Unfortunately, we currently find ourselves within a shortage period and contingency criteria will need to be enacted. Updated information will be communicated every Tuesday to inform what our current status will be for the upcoming week and will be listed as red, yellow, green or blue. We ask that providers adhere to the corresponding contingency state when ordering monoclonal therapy. For example if we are in a Yellow or Tier 2 status and the patient does not meet the criteria, set forth below we will not infuse. Please note: We are currently in yellow/tier 2 status.

The Tiered approach is supported by the data below from the CDC*. We recognize the complexity this adds to patient selection in an already challenging time. The following plan, approved by the Ethics committee will proceed as follows:

  1. Monoclonal antibodies will only be utilized for treatment of mild to moderate SARS-CoV-2. Continue to monitor communications for updates.
  2. We will infuse Douglas County residents or established LMH Health patients at this time. The rationale, approved by our Ethics committee, is that each state receives an allocation from the federal government based on the week’s previous use. The state then allocates to facilities across the state to care for patients in their region. Currently, we are being supplied at a rate that is slightly less than the demand on this facility and county. If supply and resources become more plentiful, Ethics will revisit. The quantity LMH Health is able to infuse is at the discretion of HHS & KDHE.
  3.  Green  (Tier 1): We currently have enough supply on hand to infuse 6-10 patients per day for 1 week. The standard criteria plus 1 high risk factor as set forth in the EUA.
  4.  Yellow (Tier 2): We currently have enough supply on hand to infuse 3-5 patients per day for 1 week. The standard criteria plus > 2 high risk factors.
  5.  Red  (Tier 3): We currently have less than 3 doses per day for 1 week. The standard criteria plus > 4 or more high risk factors.
  6.  Blue  (Tier 4): We have no supply on hand OR the EUA has been revoked due to insufficient activity against the current dominant strain of SARS-CoV-2.

* https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html